

**Masoud Asadi Khiavi (MD, PhDs)**

Research Center for Pharmaceutical Nanotechnology (RCPN),

Hematology and Oncology research center (HORC),

Neurosciences Research Center (NSRC),

Tabriz University of Medical Sciences, Tabriz, Iran

Mobile: +989144827480

Email: [asadim@tbzmed.ac.ir](mailto:asadim@tbzmed.ac.ir) & [makhiavi@gmail.com](mailto:makhiavi@gmail.com)

**Professional Interest:**

- Pharmacogenomics

**Teaching and supervision experience:**

2007-2008	Instructor, Tabriz University of Medical Sciences: Medical Pharmacology for Nursing BSc students
2008-2009	Instructor, Tabriz University of Medical Sciences: Hospital Pharmacy Internship for Pharmacy (PharmD) students
2009-Present	Instructor, Tabriz University of Medical Sciences, Pharmacogenomics using DNA Microarray technology for MSc & PhD students (Toxicology, Human Genetics, Medical Biotechnology, Molecular Medicine)
2010	Instructor, Zanzan University of Medical Sciences: Medical Pharmacology for Pharmacy (PharmD) students
2010 -2011	<b>Advisor for four MD &amp; MSc (Medical IT &amp; Biology students) theses</b>

## **Skills:**

1. **PC soft-wares**: (Word, Excel, PowerPoint, Photoshop, etc.), statistics and kinetics soft-wares (WinNonlin, SPSS, etc.), Matlab soft-ware, Reference managing soft-wares (EndNot, Reference manager, etc.).
2. **Stereotactic techniques** , Laboratory animal handling and **surgery techniques**
3. **Molecular genetics techniques** including: Application of the Internet-based tools and Primer design soft-wares, **PCR, RT-PCR** and **Real Time PCR**
4. Gene Expression Profiling and Gene Ontology using **DNA microarray technology** (DNA labeling using fluorescent dyes, data analysis (Image processing, data mining, Clustering and Modeling using ArrayPro and GeneMath soft-wares, Pattern recognition and Knowledge extraction using **computational intelligence** )
5. **Gene Therapy** using Antisense & siRNA therapy in cell lines

## **Selected Professional Presentations:**

1. **Asadi M.**, Hamzeiy H., Barar J., Omidi Y., Mohammadi S., WorldPharma2010 (16<sup>th</sup> World Congress of Basic and Clinical Pharmacology), **Copenhagen, Denmark, 2010**
2. Hamzeiy H.,**Asadi M.**, Mohammadi S., Eghbal M., Barar J., Omidi Y., 9<sup>th</sup> International Meeting of the “International Society for the Study of Xenobiotics” (ISSX), **Istanbul, Turkey, 2010**
3. Sadollah Mohammadi, A Garjani, M Najafi, H Hamzeiy, N Maleki-Dizaji, M Darabi, K Hassanzadeh, **Asadi M.**, WorldPharma2010 (16<sup>th</sup> World Congress of Basic and Clinical Pharmacology), **Copenhagen, Denmark, 2010**

4. Biglue M., Shahkhodabandeh S., **Asadi M.**, Barar J and Omidi Y., Iranian Scientists Approach to Breast Cancer Researches. 5<sup>th</sup> international congress of Breast Cancer, **Tehran, Iran, 2010**
5. Mashayekhi SO, Ghandforoush-Sattari M, Maleki N, **Asadi M.**, Islamboulchilar M, Parvizpour A, Alizadeh M., Learning Topics of Pharmacy Doctorate Students during Hospital Pharmacy Internship. Asian Association of Schools of Pharmacy, 4<sup>th</sup> Conference, June. 10-13, **Penang, Malaysia, 2009**
6. Barar J., **Asadi M.**, Omidi Y., Impacts of DNA microarray technology on multiple sclerosis disease. 6<sup>th</sup> international congress of Multiple Sclerosis, **Tabriz, Iran, 2009**
7. Barar J., Saei AA., **Asadi M.**, Atashpaz S., Nakhband A., Omidi Y. Microarray analysis of polycationic gene delivery nanosystems in human A431 cells. 2<sup>nd</sup> International Student Conference of Biotechnology, **Tehran, Iran, 2008**

### **Publications:**

1. **Asadi M.**, Hamzeiy H., Barar J., Omidi Y., Mohammadi S., (2010), Impacts of EGFR-antisense and carbenoxolone on cancer cell lines. *Basic & Clinical Pharmacology & Toxicology*, Volum 107: 181- 182 Doi: 10.1111/j.1742-7843.2010.00597.
2. Mohammadi S., Hamzeiy H., A. Garjani, **Asadi M.**, , Stabilization of cardiac function Methylsulfonylmethane (MSM) treatment improve hemodynamics in monocrotaline-induced pulmonary hypertension. *Basic & Clinical Pharmacology & Toxicology*, 2010, Volum 107: 465 Doi: 10.1111/j.1742-7843.2010.00597.
3. Barar J., Gumbleton M., **Asadi M.**, and Omidi Y., (2010), Barrier functionality and transport machineries of human ECV304 cells, *Medical Science Monitor*, 16(1): BR52-60.

4. Kouhi H., Hamzeiy H., Barar J., **Asadi M.**, Omidi, Y., (2009), Frequency of Five Important CYP2D6 Alleles within an Iranian Population (Eastern Azerbaijan), *Genetic Testing and Molecular Biomarkers*, 13(5): 665-670.DOI: 10.1089=gtmb.2009.0009.
5. Barar, J., **Asadi M.**, Mortazavi-Tabatabaei, S.A. and Omidi, Y., (2009), Ocular drug delivery and impacts of in-vitro cell culture models, *Journal of Ophthalmic & Vision Research*, 4(4): 238-252.
6. Mashayekhi SO, Ghandforoush-Sattari M, Maleki N, **Asadi M.**, Islamboulchilar M, Parvizpour A, Alizadeh M., (2009) Learning Topics of Pharmacy Doctorate Students during Hospital Pharmacy Internship. *Malaysian Journal of Pharmacy*; 1 (7), PPE 01.
7. Biglue M., Shakhodabandeh S., **Asadi M**, Piri Z.,Chakhmaghi N. Breast cancer in Iran: Iranian scientists research approach in Medline database. *Iranian Breast Cancer Journal*, (2009), Vol. 2, No. 2: 49-59 (in Persian)
8. Mohajjel Nayebi A. and **Asadi M**. Effect of buspirone on morphine withdrawal syndrome in mice. *Pharmaceutical Sciences*, (2009), Vol.14, No.4: 229- 235 (in Persian)
9. Moosavi MA., Moasses S., **Asadi M.**, Asvadi Kermani I., Growth inhibitory and anti-Apoptotic effects of Carbenoxolone in human leukemia NB4 cells, *Arak Medical University journal* ( accepted, in Persian)
10. Moosavi MA., Moasses S., **Asadi M.**, Asvadi Kermani I., Growth inhibitory and anti-Apoptotic effects of Carbenoxolone in human myelogenous leukemia K562 cells, *Scientific Journal of Kurdistan University of Medical Sciences*, (accepted, in Persian)
11. Moosavi MA., Moasses S., **Asadi M.**, Asvadi Kermani I., Survivin gene and its anti-apoptotic variant sur-ΔEx3 silencing associated with Carbenoxolone induced Apoptosis in human myelogenous leukemia K562 cells, *Arak Medical University journal* (accepted, in Persian)

### **Ongoing papers:**

1. Splicing variety of Survivin mRNA in CML patients (Under submission)
2. Carbenoxolone induces apoptosis and inhibits gene expression of survivin and its anti-apoptotic splice variant survivin- $\Delta$ Ex3 in human leukemia K562 cells (Under submission)
3. Impacts of gap junction blocking on MCF7 breast cancer cell line using **DNA Microarray technology** (Under submission)
4. Impacts of gap junction blocking on BT20 breast cancer cell line using **DNA Microarray technology** (Under submission)
5. Effects of modified synthesized Erlotinib on cancer Cell Lines (Under submission)
6. **DNA Microarray data clustering** using Self-organizing map for human leukemia cancers differential diagnosis (Under submission)
7. Gene regulatory network models using **Dynamic Bayesian Network on Microarray data sets** (Under submission)

### **Ongoing books/chapters:**

- Book: Programmed cell death (in Persian)

### **Awards Received:**

- Distinguished Physician by the Ministry of Health and Medical Education (1999-2000)

### **Education Workshops and Community Presentations (Selected):**

- Conference: Gene expression profiling using **DNA Microarray technology in Human Genetics**, Tabriz University of Medical Sciences, Faculty of medicine, **Tabriz, Iran, 2011**

- Workshop: **RT-PCR**, Tabriz University, **Tabriz, Iran, 2011**
- Conference: Impacts of **Nanobiotechnology** on cancer Therapy, Faculty of pharmacy, Tabriz University of Medical Sciences, **Tabriz, Iran, 2010**
- Conference: Impacts of **DNA Microarray technology** on Cancer Therapy, Faculty of pharmacy, Ardabil University of Medical Sciences **Ardabil, Iran, 2009**
- Conference: **DNA Microarray technology** in Breast Cancer, Faculty of medicine, Tabriz University of Medical Sciences, **Tabriz, Iran, 2008**

### **Organizational Memberships:**

2010-Present	<b>American College of Clinical Pharmacology (ACCP)</b>
2010-Present	Neurosciences Research Center (NSRC)
2009-Present	School of Advanced Biomedical Sciences (SABS)
2009-Present	Hematology and Oncology research center (HORC)
2005-Present	Research Center for Pharmaceutical Nanotechnology (RCPN)
1996-Present	IRI Medical Council (IRIMC)